CSC Regulatory Frameworks & Compliance 3 — Questions and Answers
Question 1: Under ACC/AHA clinical practice guidelines, which classification indicates that a procedure or treatment is NOT recommended and may be harmful?
- Class I
- Class IIa
- Class IIb
- Class III: Harm (Correct answer)
Correct answer: Class III: Harm
Class III: Harm designation indicates that the procedure or treatment has no benefit and may cause harm, representing the strongest recommendation against use.
Question 2: The National Cardiovascular Data Registry (NCDR) CathPCI Registry requires data submission for which primary purpose?
- FDA device surveillance only
- Quality benchmarking and performance improvement (Correct answer)
- Medicare claims auditing
- Physician reimbursement calculation
Correct answer: Quality benchmarking and performance improvement
The NCDR CathPCI Registry collects data on PCI procedures to enable hospitals to benchmark their outcomes against national standards and drive quality improvement.
Question 3: A hospital's cardiac surgery program has a 30-day mortality rate significantly above the STS national benchmark. Under CMS Hospital Value-Based Purchasing, what is the most likely consequence?
- Automatic decertification of the cardiac program
- Reduction in Medicare base operating DRG payments (Correct answer)
- Mandatory external review by The Joint Commission
- Requirement to suspend elective cardiac surgeries
Correct answer: Reduction in Medicare base operating DRG payments
CMS Hospital VBP withholds a percentage of Medicare base operating DRG payments and redistributes them based on quality scores including outcomes measures.
Question 4: Which regulatory framework specifically governs the safe handling, storage, and disposal of contrast media used in cardiac imaging procedures as a hazardous pharmaceutical?
- OSHA Bloodborne Pathogen Standard
- EPA Resource Conservation and Recovery Act (RCRA)
- FDA Drug Quality and Security Act
- CMS Pharmacy Services CoP (Correct answer)
Correct answer: CMS Pharmacy Services CoP
CMS Pharmacy Services Conditions of Participation (42 CFR 482.25) govern safe handling and storage of all pharmaceutical agents including contrast media in hospital settings.
Question 5: Under CMS's Two-Midnight Rule, a patient admitted for cardiac monitoring after a low-risk chest pain evaluation would most appropriately be classified as:
- Inpatient, because cardiac monitoring requires inpatient status
- Observation (outpatient), if physician expects less than two overnight stays (Correct answer)
- Inpatient, because any cardiac diagnosis requires inpatient status
- Either status, at the physician's sole discretion without documentation
Correct answer: Observation (outpatient), if physician expects less than two overnight stays
The Two-Midnight Rule classifies patients as inpatient only when the physician expects care to span two midnights; short cardiac monitoring stays typically qualify as observation.
Question 6: A cardiologist is asked to participate in a pharmaceutical company's speakers bureau for a new anticoagulant. Under CMS Open Payments (Sunshine Act), this arrangement must be reported if it exceeds:
- $0 (all payments must be reported)
- $10 aggregate per year (Correct answer)
- $100 per transfer of value
- $500 per transfer of value
Correct answer: $10 aggregate per year
The Physician Payments Sunshine Act requires manufacturers to report all payments and transfers of value to physicians exceeding $10 in aggregate per year.
Question 7: When a cardiac device manufacturer issues a Class I recall for a pacemaker lead due to a risk of cardiac perforation, the implanting facility's primary compliance obligation is to:
- Immediately explant all affected leads
- Notify affected patients and document the notification process (Correct answer)
- File a MedWatch report for each implanted device
- Suspend new implants until FDA clearance is obtained
Correct answer: Notify affected patients and document the notification process
For Class I recalls, facilities must identify and notify all affected patients per the manufacturer's recall strategy and document this process, as explantation risk may exceed recall risk.
CSC Regulatory Frameworks & Compliance 3
Under ACC/AHA clinical practice guidelines, which classification indicates that a procedure or treatment is NOT recommended and may be harmful?